Production of an anti-TM4SF5 monoclonal antibody and its application in the detection of TM4SF5 as a possible marker of a poor prognosis in colorectal cancer

International Journal of Oncology

Volumn 53, Issue 1, 2018, Pages 275-285

  Park, Byoung Kwon ^a   Park, Jae Young ^a   Kim, Te Ha ^a   Kim, Dongbum ^a   Wu, Guang ^a   Gautam, Avishekh ^a   Maharjan, Sony ^a   Lee, Su In ^a   Lee, Younghee ^b   Kwon, Hyung Joo ^a   Choi, Kyung Chan ^a  

^a Hallym University   (South Korea)

^b Chungbuk National University   (South Korea)

Author keywords

Colorectal cancer; Immunohistochemistry; Monoclonal antibody; Prognosis; Transmembrane 4 superfamily member 5 protein

Indexed keywords

GLYCOPEPTIDASE; IMMUNOGLOBULIN G2A; MEC2 CF; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; TM4SF5 PROTEIN; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G; TM4SF5 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CANCER PROGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR INVASION; VERY ELDERLY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL PROLIFERATION; COLORECTAL TUMOR; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN G; MALE; MEMBRANE PROTEINS; MICE; MIDDLE AGED; PROGNOSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85047367319     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2018.4385     Document Type: Article

References (26)

1. World Health Organization: 'GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012'. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. Retrieved April, 2015.
2. Wilkinson N and Scott-Conner CE: Surgical therapy for colorectal adenocarcinoma. Gastroenterol Clin North Am 37: 253-267, 2008.
3. Goodwin RA and Asmis TR: Overview of systemic therapy for colorectal cancer. Clin Colon Rectal Surg 22: 251-256, 2009.
4. Müller-Pillasch F, Wallrapp C, Lacher U, Friess H, Büchler M, Adler G and Gress TM: Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer. Gene 208: 25-30, 1998.
5. Lee SA, Lee SY, Cho IH, Oh MA, Kang ES, Kim YB, Seo WD, Choi S, Nam JO, Tamamori-Adachi M, et al: Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J Clin Invest 118: 1354-1366, 2008.
6. Lee SA, Ryu HW, Kim YM, Choi S, Lee MJ, Kwak TK, Kim HJ, Cho M, Park KH and Lee JW: Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology 49: 1316-1325, 2009.
7. Kwon S, Kim D, Park BK, Cho S, Kim KD, Kim YE, Park CS, Ahn HJ, Seo JN, Choi KC, et al: Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS One 7: e33121, 2012.
8. Kwon S, Kim D, Park BK, Wu G, Park MC, Ha YW, Kwon HJ and Lee Y: Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model. Oncol Rep 29: 735-740, 2013.
9. Kwon S, Kim YE, Kim D, Park BK, Wu G, Kim TH, Choi SH, Kim DS, Kwon HJ and Lee Y: Prophylactic effect of a peptide vaccine targeting TM4SF5 against colon cancer in a mouse model. Biochem Biophys Res Commun 435: 134-139, 2013.
10. Wu YB, Huang YS, Xu YP, Sun YF, Yu DL, Zhang XQ, Long X, Zhu SQ, Zhou JL and Xu JJ: A high level of TM4SF5 is associated with human esophageal cancer progression and poor patient survival. Dig Dis Sci 58: 2623-2633, 2013.
11. Wright MD, Ni J and Rudy GB: The L6 membrane proteins - a new four-transmembrane superfamily. Protein Sci 9: 1594-1600, 2000.
12. Detchokul S, Williams ED, Parker MW and Frauman AG: Tetraspanins as regulators of the tumour microenvironment: Implications for metastasis and therapeutic strategies. Br J Pharmacol 171: 5462-5490, 2014.
13. Yáñez-Mó M, Barreiro O, Gordon-Alonso M, Sala-Valdés M and Sánchez-Madrid F: Tetraspanin-enriched microdomains: A functional unit in cell plasma membranes. Trends Cell Biol 19: 434-446, 2009.
14. Jung O, Choi S, Jang SB, Lee SA, Lim ST, Choi YJ, Kim HJ, Kim DH, Kwak TK, Kim H, et al: Tetraspan TM4SF5-dependent direct activation of FAK and metastatic potential of hepatocar-cinoma cells. J Cell Sci 125: 5960-5973, 2012.
15. Kim HJ, Kwon S, Nam SH, Jung JW, Kang M, Ryu J, Kim JE, Cheong JG, Cho CY, Kim S, et al: Dynamic and coordinated single-molecular interactions at TM4SF5-enriched microdomains guide invasive behaviors in 2- and 3-dimensional environments. FASEB J 31: 1461-1481, 2017.
16. Lee SA, Kim YM, Kwak TK, Kim HJ, Kim S, Ko W, Kim SH, Park KH, Kim HJ, Cho M, et al: The extracellular loop 2 of TM4SF5 inhibits integrin alpha2 on hepatocytes under collagen type I environment. Carcinogenesis 30: 1872-1879, 2009.
17. Kwon S, Choi KC, Kim YE, Ha YW, Kim D, Park BK, Wu G, Kim DS, Lee Y and Kwon HJ: Monoclonal antibody targeting of the cell surface molecule TM4SF5 inhibits the growth of hepato-cellular carcinoma. Cancer Res 74: 3844-3856, 2014.
18. Kim YE, Kwon S, Wu G, Kim D, Park BK, Park JA, Choi KC, Kim DS, Kwon HJ and Lee Y: Therapeutic effect of a TM4SF5-specific monoclonal antibody against colon cancer in a mouse model. Oncotarget 5: 8402-8415, 2014.
19. Wu G, Kim D, Park BK, Park S, Ha JH, Kim TH, Gautam A, Kim JN, Lee SI, Park HB, et al: Anti-metastatic effect of the TM4SF5-specific peptide vaccine and humanized monoclonal antibody on colon cancer in a mouse lung metastasis model. Oncotarget 7: 79170-79186, 2016.
20. Kim D, Kwon S, Ahn CS, Lee Y, Choi SY, Park J, Kwon HY and Kwon HJ: Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA. BMB Rep 44: 758-763, 2011.
21. Park BK, Choi SH, Kim YE, Park S, Lee Y, Lee KW and Kwon HJ: Monoclonal antibodies against the human respiratory syncytial virus obtained by immunization with epitope peptides and CpG-DNA-liposome complex. Monoclon Antib Immunodiagn Immunother 34: 101-109, 2015.
22. Park BK, Lee SI, Lee Y and Kwon HJ: Effect of a monoclonal antibody against human relaxin-2 on cancer cell growth inhibition. Appl Biol Chem 59: 739-746, 2016.
23. Yokoyama WM: Production of monoclonal antibodies. Curr Protoc Cytom 2006: Appendix 3: Appendix 3J, 2006.
24. Yokoyama WM, Christensen M, Santos GD and Miller D: Production of monoclonal antibodies. Curr Protoc Immunol 74: 1-25, 2006.
25. Kim D, Kwon S, Rhee JW, Kim KD, Kim YE, Park CS, Choi MJ, Suh JG, Kim DS, Lee Y, et al: Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol 12: 29, 2011.
26. Kwon S, Kim YE, Park JA, Kim DS, Kwon HJ and Lee Y: Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model. BMB Rep 47: 215-220, 2014.